Bristol-Myers Squibb has finalized a $15 billion licensing agreement with Hengrui, a move expected to enhance its market position and investor confidence, reflected by a 0.54% rise in stock price. Additionally, the company is set to integrate AI tools from Anthropic across its operations, committing $5 million to this initiative. With projected revenues of $46 billion to $47.5 billion for 2026, analysts are increasingly optimistic, raising price targets and sustaining positive ratings for BMY.
“Bristol-Myers · inks licensing deal · 15 billion · true”
“BMY · change · stock price · +0.54%”
“Bristol-Myers · inks up to · $15 billion licensing deal · with Hengrui”
“Bristol-Myers Squibb · is bringing · Anthropic’s flagship Claude product · to more than 30,000 of its employees”
“Bristol-Myers Squibb · is using · Claude Code · to speed up its software and AI development”
“Bristol-Myers Squibb · is evaluating · the use of Claude AI agents · in areas including research, drug development, and commercial and medical affairs”
“Bristol-Myers Squibb · is continuing · a multiyear journey to deploy AI across the firm · with the agreement with Anthropic”
“Bristol Myers Squibb · reports · financial results · fourth quarter and full-year 2025”
“Bristol Myers Squibb · will host · conference call and live audio webcast · 8:00 a.m. ET on February 5, 2026”
“Bristol-Myers Squibb Company · is listed on · New York Stock Exchange · BMY”
“Bristol-Myers Squibb Company · is rated as one of · the best medical research stocks to buy according to hedge funds”
“Bernstein · reiterated its · Hold rating on Bristol-Myers Squibb Company · February 10”
